CLAIMS

What is claimed is:

1. Use of a sterile suspension formulation of nanoparticles of clobetasol propionate in the manufacture of a medicament for treating and/or preventing inflammation associated with a trauma, injury or wound, inner ear disorder, respiratory disorder, allergic rhinitis/sinusitis or asthma.

2. A sterile suspension formulation of nanoparticles of clobetasol propionate for use in the treatment and/or prevention of inflammation associated with a trauma, injury or wound, inner ear disorder, respiratory disorder, allergic rhinitis/sinusitis or asthma.

3. The use of claim 1 or the formulation for use of claim 2 for treating a joint injury, dermal injury, burn injury, or ocular burn.

4. The use of claim 1 or the formulation for use of claim 2 for treating tenosynovitis, tendinitis, or enthesitis, or arthritis.

5. The use or the formulation for use of claim 4 for reducing the complications of tenosynovitis, tendinitis, enthesitis or arthritis, including pain and/or discomfort, stiffness or decreased mobility, or improving joint, tendon, or ligament function.

6. The use of claim 1 or the formulation for use of claim 2 for treating abnormal wound healing, hypertrophic scarring, keloid formation, corneal burn wounds, corneal scarring, or impaired vision.

7. The use of any one of claims 1, 3 or 6, or the formulation for use of any one of claims 2, 3 or 6, for reducing the complications of a dermal injury, ocular burn, or abnormal wound healing.

8. The use or the formulation for use of claim 6 or 7, wherein the complications include inflammation, pain, abnormal granulation, scarring, keloid formation, contracture, deformity, pigmentation or impaired vision.

9. The use of claim 1 or the formulation for use of claim 2, wherein the inner ear disorder is hearing loss, tinnitus or vertigo.

10. The use of claim 1 or the formulation for use of claim 2, wherein the respiratory disorder is allergic rhinitis, sinusitis, or asthma.

11. The use of any one of claims 1 and 3 to 10 or the formulation for use of any one of claims 2 to 10 for reducing inflammation.

12. The use of claim 1 or the formulation for use of claim 2 for reducing inner ear dysfunction.

13. The use of any one of claims 1, 3 or 4, or the formulation for use of any one of claims 2 to 4 for reducing the complications of inner ear disorders, tenosynovitis, tendinitis, enthesitis or arthritis, including inflammation, pain, abnormal granulation, scarring, keloid formation, contracture, deformity, pigmentation or impaired vision.

14. The use of claim 1 or the formulation for use of claim 2, wherein the suspension formulation is configured for administration to the skin, eye, nose, respiratory tract, nasal mucosa, wound, tympanic membrane, middle ear, tympanic cavity, synovial space, ligament, or joint.

15. A drop, spray, mist, aerosol, gel, or injection formulation comprising a suspension of nanoparticles of clobetasol propionate.

16. The drop, spray, mist, aerosol, gel, or injection formulation of claim 15 further comprising sodium chloride, hydrogenated soybean, lecithin, anhydrous citric acid, glycerin, Poloxamer 407, polyvinyl alcohol (PVA), boric acid, edetate disodium dihydrate, benzalkonium chloride, methylcellulose, or trisodium citrate, or a combination thereof.

17. The drop, mist, spray, aerosol, gel, or injection formulation of claim 15 or 16 further comprising an antioxidant, an antimicrobial agent, an anti-inflammatory, an anesthetic, an analgesic, a lubricant, a flavoring agent or a combination thereof.

18. The injection formulation of any one of claims 15 to 17, wherein the suspension of nanoparticles is configured for injection into a hypertrophic scar or keloid, injection into the middle ear or a tympanic cavity, or injection into a joint, synovial space, tendon sheath, or ligament attachment.

19. The drop, spray, mist, aerosol, gel, or injection formulation of any one of claims 15 to 18 in sterile form.

20. A unit dose comprising a sterile suspension of nanoparticles of clobetasol propionate, where the unit dose is configured for administration by injection, topical dermal application, intra-articular injection, intradermal injection, inhalation, instillation in the nasal cavity, intratympanic injection, ocular instillation, injection into a tendon sheath or ligament attachment, or injection into a keloid or wound.

21. The unit dose of claim 20 further comprising sodium chloride, hydrogenated soybean, lecithin, anhydrous citric acid, glycerin, Poloxamer 407, polyvinyl alcohol (PVA), boric acid, edetate disodium dihydrate, benzalkonium chloride, methylcellulose, or trisodium citrate, or a combination thereof.

22. The unit dose of claim 20 or 21 further comprising an antioxidant, an antimicrobial agent, an anesthetic, an analgesic, or a combination thereof.